- Oriola as an investment
- Reports and presentations
- Financial information
- Investor calendar
- Investor relations
Business outlook for 2021, published 18 February 2021
The adjusted EBIT on a constant currency basis stays on the same level or increases from the 2020 level.
The 2020 adjusted EBIT from continuing operations was EUR 21,0 million.
The COVID-19 pandemic is expected to continue during 2021. Severity and duration of the pandemic remain unclear in Oriola’s operating environment. Oriola’s business outlook for 2021 is based on external market forecasts, agreements with pharmaceutical companies and pharmacies, and management assessments.